Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache

NCT02797951 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02797951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02797951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 13, 2016
Completion date
January 21, 2021
Enrollment
165 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic cluster headache, episodic cluster headache